These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 36233030)
41. Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain. Dekaban AS; Constantopoulos G Acta Neuropathol; 1977 Jul; 39(1):1-7. PubMed ID: 409090 [TBL] [Abstract][Full Text] [Related]
42. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses. Lin HY; Lee CL; Lo YT; Wang TJ; Huang SF; Chen TL; Wang YS; Niu DM; Chuang CK; Lin SP Mol Genet Genomic Med; 2018 Nov; 6(6):982-992. PubMed ID: 30296009 [TBL] [Abstract][Full Text] [Related]
43. Endogenous heparan sulfate and heparin modulate bone morphogenetic protein-4 signaling and activity. Khan SA; Nelson MS; Pan C; Gaffney PM; Gupta P Am J Physiol Cell Physiol; 2008 Jun; 294(6):C1387-97. PubMed ID: 18385288 [TBL] [Abstract][Full Text] [Related]
44. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? Węgrzyn G; Jakóbkiewicz-Banecka J; Narajczyk M; Wiśniewski A; Piotrowska E; Gabig-Cimińska M; Kloska A; Słomińska-Wojewódzka M; Korzon-Burakowska A; Węgrzyn A Med Hypotheses; 2010 Dec; 75(6):605-9. PubMed ID: 20732748 [TBL] [Abstract][Full Text] [Related]
45. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166 [TBL] [Abstract][Full Text] [Related]
46. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431 [TBL] [Abstract][Full Text] [Related]
47. Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice. Kowalewski B; Lamanna WC; Lawrence R; Damme M; Stroobants S; Padva M; Kalus I; Frese MA; Lübke T; Lüllmann-Rauch R; D'Hooge R; Esko JD; Dierks T Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10310-5. PubMed ID: 22689975 [TBL] [Abstract][Full Text] [Related]
48. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses. Hochuli M; Wüthrich K; Steinmann B NMR Biomed; 2003 Jun; 16(4):224-36. PubMed ID: 14558120 [TBL] [Abstract][Full Text] [Related]
49. Characterization of glycosaminoglycans stored in mucopolysaccharidosis III A: evidence for a generally occuring degradation of heparan sulfate by endoglycosidases. Kindler A; Klein U; von Figura K Hoppe Seylers Z Physiol Chem; 1977 Nov; 358(11):1431-8. PubMed ID: 411726 [TBL] [Abstract][Full Text] [Related]
50. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology. Sohn YB; Ko AR; Seong MR; Lee S; Kim MR; Cho SY; Kim JS; Sakaguchi M; Nakazawa T; Kosuga M; Seo JH; Okuyama T; Jin DK J Inherit Metab Dis; 2018 Nov; 41(6):1235-1246. PubMed ID: 29978271 [TBL] [Abstract][Full Text] [Related]
51. Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations. Jones MZ; Alroy J; Downs-Kelly E; Lucas RE; Kraemer SA; Cavanagh KT; King B; Hopwood JJ J Mol Neurosci; 2004; 24(2):277-91. PubMed ID: 15456941 [TBL] [Abstract][Full Text] [Related]
52. Altered interaction and distribution of glycosaminoglycans and growth factors in mucopolysaccharidosis type I bone disease. Kingma SDK; Wagemans T; IJlst L; Bronckers ALJJ; van Kuppevelt TH; Everts V; Wijburg FA; van Vlies N Bone; 2016 Jul; 88():92-100. PubMed ID: 27105565 [TBL] [Abstract][Full Text] [Related]
54. An At-Risk Population Screening Program for Mucopolysaccharidoses by Measuring Urinary Glycosaminoglycans in Taiwan. Lin HY; Lee CL; Lo YT; Tu RY; Chang YH; Chang CY; Chiu PC; Chang TM; Tsai WH; Niu DM; Chuang CK; Lin SP Diagnostics (Basel); 2019 Oct; 9(4):. PubMed ID: 31590383 [TBL] [Abstract][Full Text] [Related]
55. Increased deposition of glycosaminoglycans and altered structure of heparan sulfate in idiopathic pulmonary fibrosis. Westergren-Thorsson G; Hedström U; Nybom A; Tykesson E; Åhrman E; Hornfelt M; Maccarana M; van Kuppevelt TH; Dellgren G; Wildt M; Zhou XH; Eriksson L; Bjermer L; Hallgren O Int J Biochem Cell Biol; 2017 Feb; 83():27-38. PubMed ID: 27974233 [TBL] [Abstract][Full Text] [Related]
56. Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS. Menkovic I; Marchand AS; Boutin M; Auray-Blais C Diagnostics (Basel); 2019 Nov; 9(4):. PubMed ID: 31752121 [TBL] [Abstract][Full Text] [Related]
57. Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Herndon ME; Stipp CS; Lander AD Glycobiology; 1999 Feb; 9(2):143-55. PubMed ID: 9949192 [TBL] [Abstract][Full Text] [Related]
58. Anchorage of collagen-tailed acetylcholinesterase to the extracellular matrix is mediated by heparan sulfate proteoglycans. Brandan E; Maldonado M; Garrido J; Inestrosa NC J Cell Biol; 1985 Sep; 101(3):985-92. PubMed ID: 3161900 [TBL] [Abstract][Full Text] [Related]
59. Pathogenesis of Mucopolysaccharidoses, an Update. Fecarotta S; Tarallo A; Damiano C; Minopoli N; Parenti G Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260444 [TBL] [Abstract][Full Text] [Related]